Portfolio company
COUR Pharma
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
3 investors
Sectors
About
This clinical-stage biotechnology company develops nanoparticle therapies designed to restore immune tolerance for patients with autoimmune and inflammatory diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Topas Therapeutics
This biotechnology company develops nanoparticle-based therapeutics that induce immune tolerance to treat patients with autoimmune diseases, allergies and anti-drug immune responses.
Selecta Biosciences
This biopharmaceutical company develops nanoparticle immunomodulatory drugs to treat and prevent human diseases for patients with autoimmune disorders and rare genetic conditions.
Ouro Medicines
This biotechnology firm develops T-cell engager therapies to treat patients living with chronic immune-mediated diseases.
Boulevard Bio
This clinical-stage biotechnology company develops multi-specific antibody therapies for patients suffering from B cell-driven autoimmune diseases.
Beeline Medicines
This clinical-stage biotechnology company develops precision therapies for patients living with autoimmune and inflammatory diseases.
Nilo Therapeuti
This biotechnology company develops medicines that target neural circuits to treat patients with autoimmune and inflammatory diseases.
Candid Therapeutics
This clinical-stage biotechnology company develops T-cell engager antibodies for patients with autoimmune and inflammatory diseases.
Egle Therapeutics
This biotechnology company develops precision medicines that modulate regulatory T cells to treat patients with autoimmune diseases and cancer.
